Lawyers USA Your Business Partner

Texas case over Botox nerve damage deadlocks jury 

Published: March 8, 2012

Tags: Botox, hung jury

A lawyer who last year won a $212 million verdict alleging Botox caused brain damage failed to convince a jury on Feb. 15 in another case over the popular injections.

‘Ground breaking’ Botox case results in $212M jury verdict 

By: Sylvia Hsieh
Published: January 17, 2012

Tags: Allergan, Botox, botulism, brain damage, Top Ten Jury Verdicts, Top Ten Jury Verdicts of 2011

Unlike the Hollywood starlets trying to reverse gravity or other middle-aged mortals seeking to smooth out facial wrinkles, Douglas Ray Jr. went for Botox injections for reasons other than vanity.

Tort litigation trends, major verdicts make news in 2011 

Published: January 5, 2012

Tags: asbestos, Botox, brain fog, brain injury, class action, erectile dysfunction, failure to warn, frakking, hair loss, health risks, hepatitis, implied preemption, mesothelioma, natural gas, nuisance, pelvic mesh, Propecia, property devaluation, Proscar, technology, tort claims, tort climate, Twiqbal, U.S. Supreme Court

The past year featured a flurry of activity on the personal injury and tort scene, with several new drug and device developments, significant U.S. Supreme Court rulings and some staggering verdicts.

Here’s a wrap-up of the highlights of personal injury and
» Continue Reading.

‘Ground breaking’ Botox case results in $212 million jury verdict 

By: Sylvia Hsieh
Published: May 6, 2011

Tags: Allergan, Botox, botulism, brain damage

Unlike the Hollywood starlets trying to reverse gravity or other middle-aged mortals seeking to smooth out facial wrinkles, Douglas Ray Jr. went for Botox injections for reasons other than vanity.

Drug litigation in review 2010 

By: Tony Ogden
Published: January 4, 2011

Tags: Accutane, Allergan, antidepressant, Avandia, AztraZeneca, Botox, Botox litigation, Department of Justice, DOJ, epilepsy, failure to warn, GlaxoSmithKline, heart attack, hormone replacement therapy, hormone replacement therapy litigation, Johnson & Johnson, Levaquin, Neurontin, Paxil, Pfizer, Premarin, Prempro, Provera, Roche, Seroquel, Wyeth

Much like 2009, 2010 was a busy year for prescription drug suits.

Manufacturer settles suit over off-label Botox death 

By: Tony Ogden
Published: October 7, 2010

Tags: Allergan, Botox, botulism, FDA

The son and daughter of a 69-year-old woman who died after receiving Botox injections have settled their failure to warn suit against Allergan, the manufacturer of the drug.  This is the first Botox suit to settle, according Ray Chester, lead attorney for the plaintiffs.

Allergan agrees to $600 million Botox plea deal 

By: Nora Tooher
Published: September 2, 2010

Tags: Allergan, Botox, off-label marketing

Allergan has agreed to plead guilty and pay $600 million to resolve allegations it illegally promoted off-label uses of Botox.

First plaintiff’s Botox victory results in $15 million verdict 

By: Correy Stephenson
Published: May 24, 2010

Tags: Allergan, Botox, botulism, failure to warn

In the first victory for a plaintiff alleging botulism poisoning as a result of Botox injections, a former Oklahoma OB/GYN was awarded $15 million in damages earlier this month.

First Botox verdict goes to defense, but it’s just the beginning 

By: Nora Tooher
Published: March 4, 2010

Tags: Allergan, Botox, botulism, failure to warn

Allergan Corp. scored a victory in the first Botox trial, but legal experts say the defense verdict may have little impact on ongoing litigation.

Drug litigation preview 

By: Nora Tooher
Published: January 14, 2010

Tags: Avandia, Botox, Digitek, drug litigation, FDA, Food and Drug Administration, hormone replacement therapy, Neurontin, off-label uses, preemption, Prempro, Vioxx, whistleblower, Wyeth v. Levine

Plaintiffs’ lawyers are gearing up for a slew of pharmaceutical product liability trials in 2010.

While no case has the magnitude of the massive $4.85 billion Vioxx settlement in 2007, the trials represent a welcome return to courtroom action on the pharmaceutical front for plaintiffs’ lawyers.